Literature DB >> 11500835

The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity.

K Shudo1, K Kinoshita, R Imamura, H Fan, K Hasumoto, M Tanaka, S Nagata, T Suda.   

Abstract

The ectopic expression of Fas ligand (FasL/CD95L) in tissues or tumors induces neutrophil infiltration and the destruction of the tissues or the rejection of tumors. It has been suggested that the infiltrated neutrophils are responsible for the latter phenomena. FasL is synthesized as a type II transmembrane protein, and soluble FasL is produced by a proteolytic mechanism from the membrane-bound form. We previously demonstrated that uncleavable membrane-bound FasL of mice induces IL-1 beta release from inflammatory cells, and suggested that the IL-1 beta enhances neutrophil infiltration. However, recent papers reported that human soluble FasL is directly chemoattractive to neutrophils in vitro and proposed that the soluble form of FasL is responsible for its inflammatory activity. Therefore, in this report, we investigated which form is responsible for the inflammatory activities of human FasL. We produced tumor cell lines expressing one or both forms of human FasL. Cells expressing both forms or only the membrane-bound form of FasL induced neutrophil infiltration when transplanted into the peritoneal cavity of syngeneic mice, while cells expressing only the soluble form did not. Purified soluble FasL failed to induce neutrophil infiltration in vivo. IL-1 beta release from inflammatory peritoneal exudate and acceleration of tumor rejection were also mediated by membrane-bound but not soluble FasL. These results indicate that the membrane-bound form of FasL is primarily responsible for its inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500835     DOI: 10.1002/1521-4141(200108)31:8<2504::aid-immu2504>3.0.co;2-c

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

Review 1.  Control of death receptor ligand activity by posttranslational modifications.

Authors:  R Weinlich; T Brunner; G P Amarante-Mendes
Journal:  Cell Mol Life Sci       Date:  2010-03-20       Impact factor: 9.261

2.  Cancer: A wolf in wolf's clothing.

Authors:  Douglas R Green
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

3.  Fas ligand-dependent inflammatory regulation in acute myocarditis induced by Trypanosoma cruzi infection.

Authors:  Gabriel Melo de Oliveira; Rafaela Lopes Diniz; Wanderson Batista; Marcelo Meuser Batista; Cristiane Bani Correa; Tânia Cremonini de Araújo-Jorge; Andréa Henriques-Pons
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 4.  Life and death by death receptors.

Authors:  Maria Eugenia Guicciardi; Gregory J Gores
Journal:  FASEB J       Date:  2009-01-13       Impact factor: 5.191

Review 5.  The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood.

Authors:  C H Hulme; S J Brown; H R Fuller; J Riddell; A Osman; J Chowdhury; N Kumar; W E Johnson; K T Wright
Journal:  Spinal Cord       Date:  2016-12-20       Impact factor: 2.772

6.  Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Pascal Schneider; Margaret J Hosie
Journal:  Mol Immunol       Date:  2009-02-01       Impact factor: 4.407

7.  Alterations in myocardial gene expression associated with experimental Trypanosoma cruzi infection.

Authors:  Shankar Mukherjee; Fnu Nagajyothi; Aparna Mukhopadhyay; Fabiana S Machado; Thomas J Belbin; Antonio Campos de Carvalho; Fangxia Guan; Chris Albanese; Linda A Jelicks; Michael P Lisanti; Joao S Silva; David C Spray; Louis M Weiss; Herbert B Tanowitz
Journal:  Genomics       Date:  2008-03-17       Impact factor: 5.736

8.  Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus.

Authors:  Lukas Bossaller; Vijay A K Rathinam; Ramon Bonegio; Ping-I Chiang; Patricia Busto; Adam R Wespiser; Daniel R Caffrey; Quan-Zhen Li; Chandra Mohan; Katherine A Fitzgerald; Eicke Latz; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

9.  Contribution of Fas to diabetes development.

Authors:  Alexei Y Savinov; Andrew Tcherepanov; E Allison Green; Richard A Flavell; Alexander V Chervonsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

10.  Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer.

Authors:  Jaime F Modiano; Donald Bellgrau; Gary R Cutter; Susan E Lana; Nicole P Ehrhart; Ej Ehrhart; Vicki L Wilke; J Brad Charles; Sibyl Munson; Milcah C Scott; John Pozniak; Cathy S Carlson; Jerome Schaack; Richard C Duke
Journal:  Mol Ther       Date:  2012-07-31       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.